Toggle menu

DASH Trial

Start date:
June 2019

Why?

Medications to ‘thin’ the blood can have an unwanted effect on strokes caused by bleeding in the brain. Controlling bleeding is crucial in the first few hours after stroke but there is still uncertainty over the best course of treatment.

 

What?

DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.

 

https://clinicaltrials.gov/ct2/show/NCT03696121

Research Team

Allan MacRaild

Stroke Lead Research Nurse

Seona Burgess

Senior Stroke Research Nurse

Pat Taylor

Senior Stroke Research Nurse

Rachel O'Brien

Lead Research Nurse

Julia Grahamslaw

Lead Research Nurse

Fiona McCurrach

Senior Research Nurse

More EMERGE Trials

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Read more

NOVEL Study

Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)